Description: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network.
Home Page: www.wuxibiologics.com
No. 108, Meiliang Road
Wuxi,
214092
China
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Ge Li Ph.D. | Founder & Chairman |
| Dr. Zhisheng Chen | CEO & Exec. Director |
| Dr. Weichang Zhou Ph.D. | Pres of Global Biologics Devel. & Operations, CTO and Exec. Director |
| Mr. Ming Tu | CFO & Exec. VP |
| Ms. Tang Shaogui M.B.A. | VP and Head of Global Communications, Operations, Marketing & ESG |
| Dr. Jijie Gu | Exec. VP & Chief Scientific Officer |
| Ms. Eileen Wang | IR Sr. Director |
| Ms. Cong Ding J.D. | VP & Head of Legal Department |
| He Wang | Chief Compliance Officer, Sr. VP & Head of Global Compliance and Risk Management |
| Ms. Li Xiong | VP & Head of Global HR |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 30.6748 |
|---|---|
| Trailing PE: | 60.1724 |
| Price-to-Book MRQ: | 6.0334 |
| Price-to-Sales TTM: | 2.0276 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10593 |